Vera Therapeutics, Inc. Increase Decrease In Operating Lease Liability
Vera Therapeutics, Inc. (VERA) reported Increase Decrease In Operating Lease Liability of -$369.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-10
- Vera Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$187.00K.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$182.00K.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$100.00K.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$520.00K.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2025 was -$1.48M.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2024 was -$2.41M.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2023 was -$2.65M.
- Vera Therapeutics, Inc. increase decrease in operating lease liability for fiscal 2022 was -$2.60M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$369.00K 10-Q · filed 2026-08-10 | -$469.00K derived: sum of 3 quarters · filed 2026-08-10 | -$989.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | -$182.00K 10-Q · filed 2026-05-07 | -$282.00K derived: sum of 2 quarters · filed 2026-05-07 | -$802.00K derived: sum of 3 quarters · filed 2026-05-07 | -$1.27M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | -$100.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$620.00K derived: sum of 2 quarters · filed 2026-02-26 | -$1.09M derived: sum of 3 quarters · filed 2026-08-10 | -$1.48M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$520.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$989.00K derived: sum of 2 quarters · filed 2026-08-10 | -$1.38M 10-Q · filed 2025-11-05 | -$1.91M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | -$469.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | -$863.00K 10-Q · filed 2026-08-10 | -$1.39M derived: sum of 3 quarters · filed 2026-08-10 | -$2.01M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | -$394.00K 10-Q · filed 2026-05-07 | -$923.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.54M derived: sum of 3 quarters · filed 2026-05-07 | -$2.16M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$529.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.15M derived: sum of 2 quarters · filed 2026-02-26 | -$1.77M derived: sum of 3 quarters · filed 2026-02-26 | -$2.41M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$618.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$1.24M derived: sum of 2 quarters · filed 2025-11-05 | -$1.88M 10-Q · filed 2025-11-05 | -$2.53M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$623.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$1.26M 10-Q · filed 2025-08-05 | -$1.91M derived: sum of 3 quarters · filed 2026-02-26 | -$2.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$637.00K 10-Q · filed 2025-05-07 | -$1.29M derived: sum of 2 quarters · filed 2026-02-26 | -$1.94M derived: sum of 3 quarters · filed 2026-02-26 | -$2.60M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | -$649.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$1.30M derived: sum of 2 quarters · filed 2026-02-26 | -$1.97M derived: sum of 3 quarters · filed 2026-02-26 | -$2.65M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$651.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$1.32M derived: sum of 2 quarters · filed 2024-11-07 | -$2.00M 10-Q · filed 2024-11-07 | -$2.69M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$665.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.34M 10-Q · filed 2024-08-08 | -$2.04M derived: sum of 3 quarters · filed 2024-08-08 | -$2.69M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$680.00K 10-Q · filed 2024-05-10 | -$1.37M derived: sum of 2 quarters · filed 2024-05-10 | -$2.02M derived: sum of 3 quarters · filed 2024-05-10 | -$2.66M derived: sum of 4 quarters · filed 2024-05-10 |
| 2022-12-31 | -$693.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-27 | -$1.34M derived: sum of 2 quarters · filed 2024-03-27 | -$1.98M derived: sum of 3 quarters · filed 2024-03-27 | -$2.60M 10-K · filed 2024-03-27 |
| 2022-09-30 | -$647.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$1.28M derived: sum of 2 quarters · filed 2023-11-09 | -$1.91M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$636.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.26M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$626.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $0.00 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |